A case of nasal septal perforation secondary to systemic bevacizumab therapy for ovarian cancer is reported. Bevacizumab is a vascular endothelial growth factor A (VEGF-A) inhibitor that is becoming more widely utilized in the oncologic community. There is only one prior report of septal perforation secondary to bevacizumab in the Otolaryngology specific literature. The purpose of this report is: 1) to raise awareness and discuss the literature surrounding the sinonasal complications of bevacizumab and 2) provide workup and treatment recommendations based on the sum of the available literature.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k67NdV
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Find out more about the wide range of A Levels and full time courses available at Longley Park Sixth Form College, the only independent Sixt...
-
Abstract Layer-by-layer (LbL) dip coating, accompanying with the use of micelle structure, allows hydrophobic molecules to be coated on me...
-
Ketchikan to have new visiting ear, nose, throat specialist Capital city weekly Christensen will provide patients in southern Southea...
-
Aims. To evaluate the efficacy of Lian-Se formula (LSF), one Chinese herb formulation for treating sialorrhea and frequent overnight urinati...
-
Abstract Background Tumors of the spine in children are rare, and further clinical description is necessary. Objective This study in...
-
This paper presents an adaptive multiuser transceiver scheme for DS-CDMA systems in which pilot symbols are added to users’ data to estimate...
-
http://ift.tt/2sy5ibn
-
An Italian CT lung cancer screening trial has found low-dose CT screening could... Read more on AuntMinnieEurope.com Related Reading: U...
-
Abstract Background The Western Ontario Rotator Cuff Index (WORC) is a scale designed to evaluate the impact of rotator cuff (RC) disord...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου